BC
DFTX

Burleson & Co’s Definium Therapeutics DFTX Stock Holding History

Burleson & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$189 Sell
86
-86
-50% -$239 ﹤0.01% 396
2022
Q3 		$0 Buy
172
+85
+98% +$816 ﹤0.01% 456
2022
Q2 		$1K Hold
87
– – ﹤0.01% 383
2022
Q1 		$1K Hold
87
– – ﹤0.01% 372
2021
Q4 		$2K Hold
87
– – ﹤0.01% 314
2021
Q3 		$3K Buy
87
+20
+30% +$865 ﹤0.01% 303
2021
Q2 		$3K Buy
+67
New +$3.52K ﹤0.01% 309

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Burleson & Co's DFTX Position: Q4 2022 in Review

Burleson & Co reduced its Definium Therapeutics (DFTX) stake by 50% in Q4 2022, selling an estimated $239 and leaving 86 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #396.

Burleson & Co first reported a position in DFTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $3K in Q3 2021. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Burleson & Co held 86 shares of Definium Therapeutics worth $189 as of Q4 2022.
  • Burleson & Co sold 86 Definium Therapeutics shares in Q4 2022, an estimated $239.
  • Definium Therapeutics made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #396 holding.
  • Burleson & Co first reported a position in Definium Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Burleson & Co's Definium Therapeutics position peaked at $3K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.